Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

Wells Messersmith named director of CU Anschutz Cancer Center

Wells Messersmith was named director of the University of Colorado Anschutz Cancer Center, effective Oct. 1.

October 30, 2026

California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait.

October 23, 2026

Vol.52 No.39

By Arie S. Belldegrun

In Brief

Moffitt advances patient avatar technologies through $15M federal research initiative

Moffitt Cancer Center is advancing patient avatar technologies through a $15 million federally funded research initiative in collaboration with the Murtha Cancer Center Research Program at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.

October 16, 2026

Vol.52 No.38

Clinical Roundup

COA survey finds high bispecific therapy adoption among community oncology practices

The Community Oncology Alliance announced results from a national survey examining how independent community oncology practices deliver bispecific therapies on Sept. 22.

September 25, 2026

Vol.52 No.35

Cancer Policy

HRSA redrafts 340B rebate pilot program after courts block the original version

After returning to the drawing board, the Health Resources and Services Administration has announced a second iteration of the 340B Rebate Model Pilot Program, after it withdrew the original pilot earlier this year.

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.

July 31, 2026

Vol.52 No.30

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

YOU MAY BE INTERESTED IN

Wells Messersmith named director of CU Anschutz Cancer Center

California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power

Moffitt advances patient avatar technologies through $15M federal research initiative

COA survey finds high bispecific therapy adoption among community oncology practices

HRSA redrafts 340B rebate pilot program after courts block the original version

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Computational model measures key aging metric from routine biopsies, Sanford Burnham study finds

YOU MAY BE INTERESTED IN

Wells Messersmith named director of CU Anschutz Cancer Center

California’s Prop 38 is an historic approach to funding medical research, immunologyThe $8.4B bond makes a long-term investment in a field with life-saving power

Moffitt advances patient avatar technologies through $15M federal research initiative

COA survey finds high bispecific therapy adoption among community oncology practices

HRSA redrafts 340B rebate pilot program after courts block the original version

BTK A428D mutation allows blood cancers to outsmart BTK-targeted therapies, study finds

Never miss an issue!

Login

California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power